Diabetes mellitus and the liver cirrhosis

Česká verzia

Authors: T. Fejfar ¹; V. Šafka ²; V. Jirkovský ¹; J. Štefánková ³; P. Hůlek ¹
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc. ¹; Ústav fyziologie Lékařské fakulty Hradec Králové, přednostka prof. MUDr. Zuzana Červinková, CSc. ²; Diabetologická ambulance Hradec Králové ³
Published in the journal: Vnitř Lék 2011; 57(4): 368-371
Category: 12th national Symposium diabetes, "Diabetes and Gastroenterology", Hradec Kralove, 4 to 5 June 2010

Summary

Patients with liver cirrhosis have increased risk of diabetes mellitus development, especially when the underlying disease is hereditary hemochromatosis, autoimune hepatitis, non-alcoholic steatohepatitis or chronic hepatitis C. Patients with associated diabetes according to liver cirrhosis complications have worse prognosis and the therapy is influenced by both diseases. The authors bring short review of particular diseases, diagnosis and treatment strategy.

Key words:
liver cirrhosis – diabetes mellitus

Zdroje

1. Bianchi G, Marchesini G, Zoli M et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119–125.

2. Lai MS, Hsieh MS, Chiu YH et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295–1302.

3. Donadon V, Balbi M, Mas MD et al. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 2010; 30: 750–758.

4. Horák J. Genetická hemochromatóza. In: Ehrmann J, Hůlek P et al (eds). Hepatologie. 1. vyd. Praha: Grada 2010: 339–345.

5. DuBois S, Kowdley V. Review article: targeted screening for hereditary haemochromatosis in high-risc groups. Aliment Pharmacol Ther 2004; 20: 1–14.

6. Aytug S, Reich D, Sapiro LE et al. Impaired IRS-1/PI3-kinase signalling in patients with HCV: a mechanism for increase prevalence of type 2 diabetes. Hepatology 2003; 38: 1384–1392.

7. Alaei M, Negro R. Hepatitis C virus and glucose and lipid metabolism. Diabetes Metab 2008; 34: 692–700.

8. Romeo-Gómez M, Fernández-Rodriguez CM, Andrare RJ at al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48: 721–727.

9. Donadon V, Balbi M, Ghersetti M et al. Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease. World J Gastroenterol 2009; 15: 2506–2511.

10. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223–240.

11. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; 20: CD002967.

12. Romero-Gómez M, Diago M, Andrade RJ et al. Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009; 50: 1702–1708.